Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell

Jean-Francois Viallard1, Estibaliz Lazaro, Marie-Edith Lafon

  • 1Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévâque, 33604 Pessac Cedex, France. jean-francois.viallard@chu-bordeaux.fr

Leukemia & Lymphoma
|December 13, 2005
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a rare brain infection, was successfully treated with cidofovir in a patient with angioimmunoblastic T-cell lymphoma (AITL). This case highlights PML

Area of Science:

  • Neurology
  • Infectious Diseases
  • Hematology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease caused by JC virus (JCV) in immunocompromised individuals.
  • PML incidence is rising in patients with hematological malignancies, particularly B-cell disorders.
  • PML has historically shown poor response to available treatments.

Observation:

  • A patient developed PML six months prior to the diagnosis of angioimmunoblastic T-cell lymphoma (AITL).
  • This represents the first documented case of PML in the context of AITL.
  • Neurological symptoms and white matter changes on imaging prompted suspicion of PML.

Findings:

  • Successful treatment of PML was achieved using cidofovir.
  • Cidofovir demonstrated efficacy in a patient with PML and AITL.
  • The treatment course suggests cidofovir as a viable therapeutic option.

Implications:

  • PML is an increasingly recognized complication in hematological conditions beyond B-cell disorders.
  • Early suspicion and diagnosis of PML are crucial for timely intervention.
  • Cidofovir offers a promising treatment avenue for PML in immunocompromised patients, including those with AITL.